Worst Case Valeant (VRX) is a Buy - Mizuho

Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact

Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.

Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More

Is a 'Fire Sale' in Store for Valeant Pharma (VRX)?

With all hope lost, speculators wonder if a fire sale may be the last resort to stop the bleeding in Valeant Pharma (NYSE: VRX) shares.

Trades are keenly focusing on the last line in Bill Ackman's letter supporting Valeant Pharma... More

Ackman, in email, says supports Valeant CEO Pearson

BOSTON (Reuters) - Billionaire investor William Ackman on Thursday told Valeant Pharmaceuticals International Inc's (NYSE: VRX)(NYSE: VRX) chief executive that he supports him and praised management and the board of directors for considering "any and all alternatives" that would... More

Bill Ackman supports Valeant Pharma (VRX) CEO Pearson - CNBC

(Updated - November 5, 2015 2:23 PM EST)

Bill Ackman supports Valeant Pharma (NYSE: VRX) CEO Mike Pearson, according to a letter seen by CNBC.

In a letter to Mr. Person, Ackman said, "In light of recent press reports, I though it... More

Endo (ENDP) Defended at Guggenheim

Endo International (NASDAQ: ENDP) shares declined Thursday, dropping 20%. Weakness followed Q3 results and guidance, but may have more to with writedowns and read-through from other companies like Lannett (NYSE: LCI) and Valeant Pharma (NYSE: VRX), said Guggenheim analyst Louise Chen. In the analyst's view, weakness is "overdone."

"The Street appeared disappointed that ENDP wrote down some assets and we believe part of the sell-off can be attributed to broader headlines in... More

Valeant Pharma (VRX) Board Has Full Confidence in Mike Pearson - CNBC

Valeant Pharma (NYSE: VRX) says in statement CEO Mike Pearson continues to have board's full confidence; "he remains focused on running the business" - CNBC's Tirrel

HedgEye says Valeant Pharma (VRX) may fall another 75%

HedgEye says Valeant Pharma (NYSE: VRX) may fall another 75%

LINK

Streetinsider.com's Hot Lunchtime Reads 11/5: (VRX) (CAB) (QCOM) (BLRX) (RNWK)

The following is a list of notable articles to help get you through the lunch hour:Three Reasons Valeant (VRX) is Plunging Today ->... More

Three Reasons Valeant (VRX) is Plunging Today

Investors continue to scratch their head as to why Valeant Pharma (NYSE: VRX) plunged 20% today. There are three theories to explain today's wild ride. The first theory is that there was... More

BMO Capital Sees Valeant (VRX) Weakness Related to Ackman Comments that Pearson Might Have to Go

BMO Capital analyst Alex Arfaei weighed in on today's weakness in Valeant Pharmaceuticals (NYSE: VRX), saying they suspect that the decline is primarily related to Mr. Ackmans comments published today in the Wall Street Journal suggesting that Valeants CEO, Mr. Pearson, might have to go.

The article discloses conversations between Mr. Ackman and Valeants lead director, Robert Ingram. According to the article, Mr. Ackman told Mr. Ingram "If Mike [Pearson] hides in the bunker on this, he cant be CEO." Moreover, according to the article, Mr. Ackman told Mr.... More

Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows

By Svea Herbst-Bayliss and Caroline Humer

BOSTON/NEW YORK (Reuters) - Billionaire investor Bill Ackman expressed confidence in Valeant Pharmaceuticals International Inc's chief executive on Thursday as shares in the drugmaker fell as much as 20 percent to their lowest level since 2013 on concerns over its business practices.

Valeant (NYSE: VRX)(NYSE: VRX) CEO Michael Pearson has come under increasing pressure as the company's stock plunged from $263.70 on Aug. 5 to below $80 on Thursday on scrutiny over high price markups for its drugs and accusations it used a specialty pharmacy,... More

Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying Uncle

Shares of embattled pharmaceutical company Valeant Pharma (NYSE: VRX) are in free fall Thursday. Shares last traded down 18% to $75. All the talk on Wall Street is that large shareholders are finally throwing in the towel, forced or otherwise, following allegations of prescription and medicare... More

Ackman Stocks Trade Lower on Valeant (VRX) Free-Fall

A number of Bill Ackman stocks are getting hit with today's free fall in Valeant (NYSE: VRX) (-16%): Zoetis (NYSE: ZTS) (-3%), Mondelez (NASDAQ: MDLZ) (-0.5%), Air Product (NYSE:... More

Valeant Pharma (VRX) Plunges Over 16%

Sell-off in Valeant Pharma (NYSE: VRX) intensifies. Shares down 16%. Chatter liquidation by large holders